{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:36:07Z","timestamp":1791218167355,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"abstract":"Summary<\/jats:title>\n \n Background and objectives<\/jats:title>\n Sclerostin, a bone antianabolic peptide involved in osteoporosis, is elevated in patients undergoing maintenance dialysis. However, there are no data for patients with early CKD.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n Between January and July 2010, serum sclerostin and GFR (calculated by inulin clearance) were measured in 90 patients with CKD. Fasting blood samples were also drawn for determination of calcium, phosphorus, parathyroid hormone, bone alkaline phosphatase, and 25-OH vitamin D.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Median GFR was 66.5 (interquartile range, 40.0\u201388.3) ml\/min per 1.73 m\n 2<\/jats:sup>\n . Median sclerostin level was 53.5 (interquartile range, 37.5\u201377.2) pmol\/L, was higher in patients with a GFR <60 ml\/min per 1.73 m\n 2<\/jats:sup>\n , and was highest in those with ESRD. Sclerostin levels were significantly more elevated in men than women (\n P<\/jats:italic>\n <0.05). An inverse relationship was found between sclerostin and GFR (\n r<\/jats:italic>\n =\u22120.58;\n P<\/jats:italic>\n <0.001), and a positive correlation was seen with age (\n r<\/jats:italic>\n =0.34;\n P<\/jats:italic>\n <0.01) and serum phosphate (\n r<\/jats:italic>\n =0.26;\n P<\/jats:italic>\n =0.02). In multiple regression analyses, GFR, sex, and serum phosphate were the only variables associated with serum sclerostin (\n P<\/jats:italic>\n <0.001). Age lost its relationship with sclerostin level.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This is the first study reporting higher serum sclerostin levels starting at CKD stage III. GFR, sex, and serum phosphate were the only measures associated with sclerostin level, suggesting that the effect of age reported in the literature might instead be attributable to the altered renal function in the elderly. Correcting the serum phosphorus level may be associated with lower sclerostin levels.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.07670712","type":"journal-article","created":{"date-parts":[[2013,2,22]],"date-time":"2013-02-22T00:33:34Z","timestamp":1361493214000},"page":"819-823","source":"Crossref","is-referenced-by-count":183,"title":["The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD"],"prefix":"10.2215","volume":"8","author":[{"given":"Solenne","family":"Pelletier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Dubourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoumeur","family":"Hadj-Aissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Fouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20230811","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cytogfr.2005.02.005","article-title":"SOST\/sclerostin, an osteocyte-derived negative regulator of bone formation.","volume":"16","author":"van Bezooijen","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"R2-18-20230811","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","article-title":"Sclerostin: Current knowledge and future perspectives.","volume":"87","author":"Moester","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"R3-18-20230811","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1359\/jbmr.090411","article-title":"Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt\/beta-catenin signaling.","volume":"24","author":"Lin","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R4-18-20230811","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00198-010-1194-5","article-title":"Osteocyte: The unrecognized side of bone tissue.","volume":"21","author":"Rochefort","year":"2010","journal-title":"Osteoporos Int"},{"key":"R5-18-20230811","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/jor.22109","article-title":"Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats","volume":"30","author":"McDonald","year":"2012","journal-title":"J Orthop Res"},{"key":"R6-18-20230811","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R7-18-20230811","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2215\/CJN.01370211","article-title":"Sclerostin: Just one more player in renal bone disease?","volume":"6","author":"Dr\u00fceke","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R8-18-20230811","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ndt\/gfr270","article-title":"Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.","volume":"27","author":"Cejka","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R9-18-20230811","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/gfh568","article-title":"Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function.","volume":"20","author":"Guebre-Egziabher","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R10-18-20230811","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ab.2010.06.016","article-title":"Adaptation of an enzymatic polyfructosan assay to clinical practice.","volume":"405","author":"Dubourg","year":"2010","journal-title":"Anal Biochem"},{"key":"R11-18-20230811","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1210\/jc.2011-2958","article-title":"Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes.","volume":"97","author":"Gennari","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-18-20230811","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2011-2152","article-title":"Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults.","volume":"97","author":"Amrein","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-18-20230811","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1681\/ASN.2004100835","article-title":"Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome.","volume":"16","author":"Davies","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R14-18-20230811","first-page":"358","article-title":"Downregulation of SOST\/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes.","volume":"6","author":"Bellido","year":"2006","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"R15-18-20230811","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1210\/jc.2010-0720","article-title":"Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women.","volume":"95","author":"Drake","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-18-20230811","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/jc.2009-2283","article-title":"Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.","volume":"95","author":"Mirza","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-18-20230811","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jbmr.128","article-title":"Regulation of circulating sclerostin levels by sex steroids in women and in men.","volume":"26","author":"M\u00f6dder","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R18-18-20230811","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2215\/CJN.06550810","article-title":"Sclerostin and Dickkopf-1 in renal osteodystrophy.","volume":"6","author":"Cejka","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-18-20230811","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/jbmr.1630","article-title":"Repression of osteocyte Wnt\/\u03b2-catenin signaling is an early event in the progression of renal osteodystrophy.","volume":"27","author":"Sabbagh","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R20-18-20230811","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1681\/ASN.2006050490","article-title":"Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy.","volume":"18","author":"Mathew","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R21-18-20230811","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.","volume":"26","author":"M\u00f6dder","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R22-18-20230811","doi-asserted-by":"crossref","first-page":"E1159","DOI":"10.1210\/jc.2011-0254","article-title":"Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays.","volume":"96","author":"McNulty","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-18-20230811","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2009.374","article-title":"Parathyroid hormone measurement in CKD.","volume":"77","author":"Souberbielle","year":"2010","journal-title":"Kidney Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201305000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:07Z","timestamp":1786369387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201305000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.07670712","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}